Over the past decade, knowledge of the pathogenesis and natural history of type 1 diabetes
has grown substantially, particularly with regard to disease prediction and heterogeneity …

Autoimmune diseases are caused by immune cells attacking the host tissues they are
supposed to protect. Recent advances suggest that maintaining a balance of effector and …

Protégé was a phase 3, randomized, double-blind, parallel, placebo-controlled 2-year study
of three intravenous teplizumab dosing regimens, administered daily for 14 days at baseline …

There are three prerequisites for development of the autoimmune disease type 1 diabetes
(T1D). First, β cell-reactive T cells need to be activated; second, the response needs to be …

Type 1 diabetes mellitus (T1DM) is the result of autoimmune destruction of pancreatic β cells
in genetically predisposed individuals with impaired immune regulation. The insufficiency in …

Regulatory T cells (Tregs) are responsible for the maintenance of peripheral tolerance.
Animal studies have shown that administration of Tregs can prevent type 1 diabetes (DM1) …

The article presents a part of the guidelines on pediatric diabetes in the International Society
for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines …

Immunotherapies for type 1 diabetes mellitus (T1DM) have been the focus of intense basic
and clinical research over the past few decades. Restoring β-cell function is the ultimate …

Immune-based therapies that prevent type 1 diabetes or preserve metabolic function
remaining at diagnosis have become a major objective for funding agencies and …

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease that results from
autoreactive T cells destroying insulin‐producing pancreatic beta (β) cells. The development …